Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Combination Trial of BLU-667 and Osimertinib in Treatment-Resistant, EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) Harboring an Acquired RET Alteration

Next Previous
Search
Trial Profile

A Phase 2 Combination Trial of BLU-667 and Osimertinib in Treatment-Resistant, EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) Harboring an Acquired RET Alteration

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 07 Aug 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Osimertinib (Primary) ; Pralsetinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors Blueprint Medicines

    • Most Recent Events

    • 01 Aug 2019 According to a Blueprint Medicines media release, this trial is expected to initiate by the end of 2019.
    • 02 Apr 2019 New trial record
    • 27 Mar 2019 According to a Blueprint Medicines media release, this trial is one of the trials which will be funded by the the net proceeds of the public offering announced today by the company.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top